Enliven Therapeutics, Inc. (ELVN)
| Market Cap | 4.31B +365.0% |
| Revenue (ttm) | n/a |
| Net Income | -105.93M |
| EPS | -1.67 |
| Shares Out | 73.27M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 350,220 |
| Open | 57.67 |
| Previous Close | 58.06 |
| Day's Range | 56.69 - 58.90 |
| 52-Week Range | 14.79 - 62.32 |
| Beta | 0.24 |
| Analysts | Strong Buy |
| Price Target | 72.22 (+22.78%) |
| Earnings Date | Aug 5, 2026 |
About ELVN
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and othe... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for ELVN stock is "Strong Buy." The 12-month stock price target is $72.22, which is an increase of 22.78% from the latest price.
News
Enliven price target raised to $75 from $60 at Baird
Baird raised the firm’s price target on Enliven (ELVN) to $75 from $60 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results which…
Enliven price target raised to $82 from $80 at Stifel
Stifel analyst Dara Azar raised the firm’s price target on Enliven (ELVN) to $82 from $80 and keeps a Buy rating on the shares.
Enliven price target lowered to $78 from $80 at Guggenheim
Guggenheim lowered the firm’s price target on Enliven (ELVN) to $78 from $80 and keeps a Buy rating on the shares after the company reported Q2 results and provided a…
Enliven price target raised to $80 from $67 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Enliven (ELVN) to $80 from $67 and keeps a Buy rating on the shares.
Enliven price target raised to $68 from $55 at Clear Street
Clear Street analyst Kaveri Pohlman raised the firm’s price target on Enliven (ELVN) to $68 from $55 and keeps a Buy rating on the shares. Enliven remains on track to…
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update
Announced positive Phase 1 clinical data for ELVN-001 in CML, demonstrating encouraging ELVN-001 efficacy data and a favorable safety and tolerability profile Reached alignment with the FDA on key Ph...
Enliven Therapeutics Quarterly report: Q2 2026
Enliven Therapeutics has published its Q2 2026 quarterly earnings report on August 5, 2026.
Enliven Therapeutics Earnings release: Q2 2026
Enliven Therapeutics released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Enliven price target raised to $67 from $59 at Goldman Sachs
Goldman Sachs analyst Salveen Richter raised the firm’s price target on Enliven (ELVN) to $67 from $59 and keeps a Buy rating on the shares.
Enliven price target raised to $65 from $56 at H.C. Wainwright
H.C. Wainwright analyst Robert Burns raised the firm’s price target on Enliven (ELVN) to $65 from $56 and keeps a Buy rating on the shares after raising the firm’s view…
Enliven price target raised to $80 from $60 at Stifel
Stifel raised the firm’s price target on Enliven (ELVN) to $80 from $60 and keeps a Buy rating on the shares. The firm is “more bullish” on its second-line and…
Enliven price target raised to $70 from $45 at JonesResearch
JonesResearch raised the firm’s price target on Enliven (ELVN) to $70 from $45 and keeps a Buy rating on the shares. The firm updated the company’s model to reflect its…
Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares
BURLINGAME, Calif., June 15, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and developmen...
Why Is Enliven Therapeutics Stock (ELVN) Up Today?
Enliven Therapeutics stock was up on news of an upsized public offering.
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and developmen...
Enliven announces $250M common stock offering
Enliven (ELVN) Therapeutics announced that it has commenced an underwritten public offering of $250M of shares of its common stock and, in lieu of common stock to investors who so…
Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and developmen...
Enliven Therapeutics Transcript: Study update
ELVN-001, a highly selective ATP-competitive BCR-ABL1 TKI, showed strong efficacy and a favorable safety profile in heavily pretreated CML patients, including those with prior asciminib exposure. Phase III trials are set to begin, aiming to establish best-in-class status across multiple lines of therapy.
Enliven Therapeutics Press release: Study update
Enliven Therapeutics issued a press release on June 11, 2026, disclosing material business information to investors.
Enliven Therapeutics Slides: Study update
Enliven Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 11, 2026.
Enliven up 15% to $42.50 after positive data from Phase 1 ENABLE trial
08:15 EDT Enliven (ELVN) up 15% to $42.50 after positive data from Phase 1 ENABLE trial
Enliven’s ELVN-001 shows efficacy in Phase 1 myeloid leukemia trial
Enliven (ELVN) Therapeutics presented updated positive data from the Phase 1 ENABLE clinical trial evaluating ELVN-001 in patients with previously treated chronic myeloid leukemia, or CML. The company...
Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components
61% overall MMR and 48% MMR achievement by 24 weeks in the 80 mg QD Phase 1b cohort 67% overall MMR and 55% MMR achievement by 24 weeks in all Phase 1b patients who had previously received 1 or 2 prio...